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Introduction
Vestibular migraine (VM) has become a well-defined
diagnostic entity, based on recurrent vertigo attacks,
unexplained by other central or peripheral otologic
abnormalities, occurring in patients with a history of
migraine headache. The duration of vertigo attacks varies
from seconds to days, usually lasting minutes to hours,
mostly occurring independently of headaches.
Background and objective
This was a retrospective, multicentric, open-label investi-
gation with the aim to assess the efficacy of an oral dose
of almotriptan (ALM) 12.5 mg in the treatment for acute
vertigo attacks in VM, defined according to the ICHD
criteria, 3rd edition, beta version (2013).
This triptan, a selective 5-HT(1B/1D) receptor agonist,
since its introduction in the market in 2001, has emerged
as the one with the best efficacy and tolerability profile in
acute migraine treatment.
Materials and methods
The study included 26 subjects with VM (25 F, 1 M),
aged from 19 to 53 years (mean, 30.0 years), reporting
vertigo in more than 50% of attacks, a history of migraine
for at least one year, onset of migraine before the age of
50. Three (11%) of the 26 subjects were lost to follow up;
five (19%) discontinued the ALM treatment due to
adverse events or any other causes.
At the time of the prescription the patients were drug-
free and did not receive any prophylactic therapy.
The data were recorded in a headache diary: the inten-
sity of vertigo attacks was assessed by a 3-score scale (with
“1” indicating mild vertigo, “2” medium intensity and “3”
the worst vertigo imaginable), while the therapeutic
response to vertigo attacks by a 4-score scale (with “0”
indicating any change, “1” under 50% reduction, “2” over
50% reduction and “3” the complete disappearance of ver-
tigo). Almotriptan was administered as a single 12.5 mg
tablet with the advise to take the drug within 1 h of onset
of vertigo attack.
Follow-up was performed every month for the follow-
ing three months after the ALM treatment initiation
and the response on vertigo attacks during the study
were considered as the main and primary outcome,
while secondary variable was the effect on pain relief at
2 and 4 hours.
From the first visit onward, patients reported if they
had experienced any adverse events.
Statistical analysis of data was carried out using student
t-test.
Results
Eighteen patients were examined; they reported 27 vertigo
attacks in the course of the three-month follow-up, with
mean intensity scores ranging between “2” (24%) and “3”
(76%).
Among all the patients, 10 (55%) reported complete
disappearance of vertigo, 5 (28 %) over 50% reduction
and 3 (16%) under 50% reduction. Also, the pain relief
were significantly reduced since the first month and
confirmed in the following two months (p < 0.001).
These data suggest a benefit from almotriptan at the oral
dose of 12.5 mg in 83% of the patients with vestibular
migraine attacks; good was the tolerability profile.
Conclusions
This study suggests that almotriptan is effective and safe
in reducing both vertigo and headache among patients
who suffer from Vestibular migraine. This will have to
be reconfirmed in a large scale, randomized, controlled
clinical trial.
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